Vyvgart fails Phase 3 test in Sjögren's disease
Argenx said Vyvgart did not perform better than placebo in a Phase 3 study of people with Sjögren's disease. The condition is a long-term autoimmune disorder. The result marks an unexpected late-stage failure for the company.
Expanded Detail
[paragraph]
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Related stories
Argenx ends Sjögren's Phase 3 after miss, while celiac study succeeds · Drug development
Firmonertinib misses efficacy endpoints in Phase 3 lung cancer trial, triggering market decline · Cancer research
Oral Deucrictibant Shows Fast Relief in Phase 3 Hereditary Angioedema Trial · Drug development
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease.” Browse more stories.